Inger Kristin Larsen1, Milada Småstuen2, Tom Børge Johannesen2, Frøydis Langmark2, Donald Maxwell Parkin3, Freddie Bray4, Bjørn Møller2. 1. Department of Clinical and Registry-based Research, Cancer Registry of Norway, Institute of Population-based Cancer Research, Fridjof Nansens vei 19, Postbox 5313, Majorstuen, N-0304 Oslo, Norway. Electronic address: inger.kristin.larsen@kreftregisteret.no. 2. Department of Clinical and Registry-based Research, Cancer Registry of Norway, Institute of Population-based Cancer Research, Fridjof Nansens vei 19, Postbox 5313, Majorstuen, N-0304 Oslo, Norway. 3. Clinical Trials Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK; Cancer Research UK, Centre for Epidemiology, Mathematics and Statistics, London, UK. 4. Department of Clinical and Registry-based Research, Cancer Registry of Norway, Institute of Population-based Cancer Research, Fridjof Nansens vei 19, Postbox 5313, Majorstuen, N-0304 Oslo, Norway; Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Norway.
Abstract
AIM: To provide a comprehensive evaluation of the quality of the data collected on both solid and non-solid tumours at the Cancer Registry of Norway (CRN). METHODS: Established quantitative and semi-quantitative methods were used to assess comparability, completeness, accuracy and timeliness of data for the period 1953-2005, with special attention to the registration period 2001-2005. RESULTS: The CRN coding and classification system by and large follows international standards, with some further subdivisions of morphology groupings performed in-house. The overall completeness was estimated at 98.8% for the registration period 2001-2005. There remains a variable degree of under-reporting particularly for haematological malignancies (C90-95) and tumours of the central nervous system (C70-72). For the same period, 93.8% of the cases were morphologically verified (site-specific range: 60.0-99.8%). The under-reporting in 2005 due to timely publication is estimated at 2.2% overall, based on the number of cases received at the registry during the following year. CONCLUSION: This review suggests the routines in place at the CRN yields comparable data that can be considered reasonably accurate, close-to-complete and timely, thereby justifying our policy of the reporting of annual incidence one year after the year of diagnosis.
AIM: To provide a comprehensive evaluation of the quality of the data collected on both solid and non-solid tumours at the Cancer Registry of Norway (CRN). METHODS: Established quantitative and semi-quantitative methods were used to assess comparability, completeness, accuracy and timeliness of data for the period 1953-2005, with special attention to the registration period 2001-2005. RESULTS: The CRN coding and classification system by and large follows international standards, with some further subdivisions of morphology groupings performed in-house. The overall completeness was estimated at 98.8% for the registration period 2001-2005. There remains a variable degree of under-reporting particularly for haematological malignancies (C90-95) and tumours of the central nervous system (C70-72). For the same period, 93.8% of the cases were morphologically verified (site-specific range: 60.0-99.8%). The under-reporting in 2005 due to timely publication is estimated at 2.2% overall, based on the number of cases received at the registry during the following year. CONCLUSION: This review suggests the routines in place at the CRN yields comparable data that can be considered reasonably accurate, close-to-complete and timely, thereby justifying our policy of the reporting of annual incidence one year after the year of diagnosis.
Authors: Morten Valberg; Tom Grotmol; Steinar Tretli; Marit B Veierød; Tron A Moger; Susan S Devesa; Odd O Aalen Journal: Eur J Epidemiol Date: 2016-07-18 Impact factor: 8.082
Authors: Solveig Hofvind; Per Skaane; Joann G Elmore; Sofie Sebuødegård; Solveig Roth Hoff; Christoph I Lee Journal: Radiology Date: 2014-04-01 Impact factor: 11.105
Authors: R Troisi; T Grotmol; J Jacobsen; S Tretli; H T Sørensen; M Gissler; R Kaaja; N Potischman; A Ekbom; R N Hoover; O Stephansson Journal: J Dev Orig Health Dis Date: 2013-02 Impact factor: 2.401
Authors: Camilla Sköld; Tone Bjørge; Anders Ekbom; Anders Engeland; Mika Gissler; Tom Grotmol; Laura Madanat-Harjuoja; Anne Gulbech Ording; Olof Stephansson; Britton Trabert; Steinar Tretli; Rebecca Troisi; Henrik Toft Sørensen; Ingrid Glimelius Journal: Int J Cancer Date: 2018-07-10 Impact factor: 7.396
Authors: Rebecca Troisi; Anne Gulbech Ording; Tom Grotmol; Ingrid Glimelius; Anders Engeland; Mika Gissler; Britton Trabert; Anders Ekbom; Laura Madanat-Harjuoja; Henrik Toft Sørensen; Steinar Tretli; Tone Bjørge Journal: Int J Cancer Date: 2018-08-10 Impact factor: 7.396
Authors: Nicolien T van Ravesteyn; Jeroen J van den Broek; Xiaoxue Li; Harald Weedon-Fekjær; Clyde B Schechter; Oguzhan Alagoz; Xuelin Huang; Donald L Weaver; Elizabeth S Burnside; Rinaa S Punglia; Harry J de Koning; Sandra J Lee Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583